Wegovy Pill Holds Up in the Real World: Patients Lose About 6% of Their Weight in Three Months

The new pill version of Wegovy appears to be working about as well in everyday use as it did in clinical trials, according to the first large set of real-world results. Patients who stayed on the daily tablet lost an average of 6.2 percent of their body weight over three months, according to data from drugmaker Novo Nordisk due to be presented at the ObesityWeek conference in Washington, Reuters reported in a story carried by CTV News ^[1].

For a 220-pound adult, that works out to roughly 13 to 14 pounds in about 12 weeks, without a needle.

What the Data Show

The analysis covered 5,872 adults on the Ro telehealth platform who had never taken a weight-loss drug before and who stayed on the pill for the full three months, according to the report ^[1]. They started treatment between Jan. 5 and Feb. 7 of this year ^[1]. About three in five lost at least 5 percent of their body weight, and roughly one in six lost at least 10 percent ^[1].

Novo's chief scientific officer said the result broadly matched the 5.5 percent weight loss at 12 weeks seen in the company's late-stage trial of the pill, according to the report ^[1].

The new figures build on an earlier look at a different group. In September, Novo presented real-world data from its OCTANE analysis at the European Association for the Study of Diabetes meeting, showing that people who switched from weight-loss injections to the Wegovy pill lost an average of 4.1 percent of their body weight, about 8.8 pounds, after three months ^[2][3]. The company noted that those results came from routine telehealth care, where the timing and completeness of data vary and some information is self-reported ^[3].

Read the Fine Print

These are encouraging numbers, but they come with important limits. The data were supplied by the company and drawn from a single telehealth platform, not from a randomized trial with a comparison group ^[1]. The analysis also counted only people who stayed on the pill for all three months ^[1]. People who quit early because of side effects, cost or disappointing results are not reflected in the average, which can make a drug look better than it will for everyone who tries it.

Three months is also a short window. Weight loss with these medicines usually continues for many months, and the real question for patients and doctors is what happens at one year and beyond, and how much weight returns if someone stops.

Why It Matters for Your Heart

The reason doctors care so much about these drugs goes beyond the scale. In March 2024, the Food and Drug Administration approved injectable Wegovy to reduce the risk of heart attack, stroke and cardiovascular death in adults with heart disease and obesity or overweight, based on a large trial that found a 20 percent relative reduction in those events, CNBC reported ^[4]. It was the first time the FDA approved a weight-loss drug for that purpose ^[4].

Related More Than 10,000 Death Claims: The 9/11 Toll Still Rising a Quarter-Century After the Towers Fell

Heart disease remains the leading killer of American men and women, and excess weight is one of the risks people can do something about. A pill that is easier to take than a weekly shot could help more patients get started. That does not mean the pill carries the same proven heart benefit yet; that evidence came from the injectable version, and the pill will need its own long-term data.

A Word of Common Sense

No pill replaces the basics. Eating sensibly, moving every day, sleeping well and staying connected to family and church all protect the heart, and they cost nothing. These medicines can be a real help for people who have struggled for years, but they are prescription drugs with side effects, and they should be used under a doctor's care.

What Comes Next

The full results are set to be presented at ObesityWeek, where researchers and physicians will be able to examine the data more closely ^[1]. Patients considering the pill should ask their doctor about side effects, cost and insurance coverage, and about how long they would need to stay on it. As more real-world evidence arrives, the picture of how well these drugs work for ordinary Americans, not just trial volunteers, will become much clearer.